Figures & data
Figure 1 Patient at baseline (a–c) and after 16 weeks (d–f) of treatment with risankizumab.
Data Sharing Statement
Data are reported in the current study.
Clinical, Cosmetic and Investigational Dermatology
Volume 16, 2023 - Issue
CASE REPORT
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
, 
, , , , , & show all
Angelo RuggieroSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italyhttps://orcid.org/0000-0002-4658-7391View further author information
https://orcid.org/0000-0002-4658-7391View further author information, , , Antonio PortarapilloSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italyhttps://orcid.org/0009-0004-8445-7135View further author information
https://orcid.org/0009-0004-8445-7135View further author information, , Fabrizio MartoraSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italyhttps://orcid.org/0000-0003-2523-050XView further author information
https://orcid.org/0000-0003-2523-050XView further author information & Luca PotestioSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
https://orcid.org/0000-0001-5940-0592View further author information
https://orcid.org/0000-0001-5940-0592View further author information show all